×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
NeuBase Therapeutics plans dissolution as finances fall apart
Technical.ly
Once-promising Pittsburgh biotech firm shutting down for good · Just a year ago, NeuBase's CEO was optimistic, but its board has now determined...
2 months ago
NeuBase Therapeutics board approves plan to dissolve company
The Business Journals
NeuBase Therapeutics' board of directors voted Thursday to dissolve and liquidate the Pittsburgh-based biotech firm, according to a document...
3 months ago
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
InvestorPlace
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today? · NeuBase Therapeutics (NBSE) stock is down on Tuesday after announcing a special...
2 months ago
Small biotech ends stealth gene editing mission, seeks sale
Fierce Biotech
Gene editing biotech NeuBase Therapeutics is stopping program development and looking for a sale after its board of directors voted to close...
9 months ago
Pittsburgh's NeuBase Therapeutics targets incurable disease with licensing agreement
Pittsburgh Post-Gazette
NeuBase Therapeutics Inc. is licensing its treatment for Huntington's disease to Helexva Inc., a startup with five part-time employees that...
9 months ago
Delisting of Securities of Better Therapeutics, Inc.; Tritium DCFC Limited; Arcimoto, Inc.; Next.e.GO N.V.; Acutus Medical ...
WKBN.com
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Better...
2 weeks ago
NeuBase Therapeutics Plans Dissolution and Asset Liquidation - TipRanks.com
Tipranks
NeuBase Therapeutics Inc (NBSE) has released an update. NeuBase Therapeutics, Inc. is set to dissolve, liquidate its assets, and distribute them to...
3 months ago
Why Neubase Therapeutics (NBSE) Shares Are Nosediving
Benzinga
According to data from Benzinga Pro, NBSE has a 52-week high of $5.40 and a 52-week low of $0.59. Market News and Data...
2 months ago
Ohr Pharmaceutical pushes for merger with NeuBase for oligonucleotide platform - BioProcess Insider
BioProcess International
Ohr Pharmaceutical has urged its shareholders to vote for a merger with Neubase Therapeutics at a special meeting this week, creating an entity focused on...
2 months ago
NeuBase Therapeutics sets shareholder meeting on dissolution plan
The Business Journals
NeuBase Therapeutics sets shareholder meeting on dissolution plan · Pittsburgh biotech firm's board decides to dissolve company · CMU halts...
2 months ago